Bempikibart Hits in Phase 2a Alopecia Trial, Registrational Program Set for H1 2027
QTTB has more than doubled off its 52-week low of $1.54 on elevated volume (4.4× avg).
Summary
Q32 Bio's bempikibart delivered a 35.3% mean SALT reduction at 36 weeks in the SIGNAL-AA Part B trial, with 40% of patients hitting SALT-20. Durability signals extended through Week 52, including one complete responder. The clean safety profile—no treatment-related serious adverse events—de-risks the asset ahead of a planned registrational program in H1 2027. This follows a $55M private placement in May and a $300M shelf registration in June, giving the company capital to advance. The stock is trading near its 52-week high, reflecting rising expectations for this program, and shares exploded on the positive trial results.
At the time of this announcement, QTTB was trading at $19.31 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $265.5M. The 52-week trading range was $1.54 to $15.02. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.